Sean Laaman
Stock Analyst at Morgan Stanley
(4.69)
# 124
Out of 5,127 analysts
24
Total ratings
73.68%
Success rate
21.36%
Average return
Main Sectors:
Stocks Rated by Sean Laaman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Maintains: Equal-Weight | $48 → $49 | $42.98 | +14.01% | 6 | Feb 2, 2026 | |
| AXSM Axsome Therapeutics | Downgrades: Equal-Weight | $196 → $204 | $184.30 | +10.69% | 4 | Jan 8, 2026 | |
| BBIO BridgeBio Pharma | Initiates: Overweight | $96 | $72.47 | +32.47% | 1 | Jan 6, 2026 | |
| CERT Certara | Maintains: Equal-Weight | $16 → $12 | $7.00 | +71.43% | 2 | Dec 18, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Overweight | $20 | $10.84 | +84.50% | 1 | Dec 5, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Overweight | $34 | $17.92 | +89.73% | 1 | Nov 21, 2025 | |
| IRON Disc Medicine | Maintains: Overweight | $90 → $115 | $74.75 | +53.85% | 3 | Oct 30, 2025 | |
| RMD ResMed | Maintains: Overweight | $298 → $304 | $263.54 | +15.35% | 2 | Oct 21, 2025 | |
| ONC BeOne Medicines AG | Maintains: Overweight | $350 → $383 | $353.43 | +8.37% | 2 | Oct 20, 2025 | |
| ALEC Alector | Assumes: Underweight | $3 → $1.5 | $1.96 | -23.47% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $67 | $80.22 | -16.48% | 1 | Feb 14, 2025 |
Exelixis
Feb 2, 2026
Maintains: Equal-Weight
Price Target: $48 → $49
Current: $42.98
Upside: +14.01%
Axsome Therapeutics
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $196 → $204
Current: $184.30
Upside: +10.69%
BridgeBio Pharma
Jan 6, 2026
Initiates: Overweight
Price Target: $96
Current: $72.47
Upside: +32.47%
Certara
Dec 18, 2025
Maintains: Equal-Weight
Price Target: $16 → $12
Current: $7.00
Upside: +71.43%
BridgeBio Oncology Therapeutics
Dec 5, 2025
Initiates: Overweight
Price Target: $20
Current: $10.84
Upside: +84.50%
MapLight Therapeutics
Nov 21, 2025
Initiates: Overweight
Price Target: $34
Current: $17.92
Upside: +89.73%
Disc Medicine
Oct 30, 2025
Maintains: Overweight
Price Target: $90 → $115
Current: $74.75
Upside: +53.85%
ResMed
Oct 21, 2025
Maintains: Overweight
Price Target: $298 → $304
Current: $263.54
Upside: +15.35%
BeOne Medicines AG
Oct 20, 2025
Maintains: Overweight
Price Target: $350 → $383
Current: $353.43
Upside: +8.37%
Alector
Mar 7, 2025
Assumes: Underweight
Price Target: $3 → $1.5
Current: $1.96
Upside: -23.47%
Feb 14, 2025
Assumes: Overweight
Price Target: $67
Current: $80.22
Upside: -16.48%